Nancy L Carteron, MD
Rheumatology · Berkeley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 2
- Since medical school
- 44 years
- Johns Hopkins University School of Medicine, 1982
Offices
2 locations · Regents of the University of California at Berkeley · University of California San Francisco
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Carteron’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G52227 · Current
Licensed to practise in California · since 1984 · expires 2028-03-31 · Johns Hopkins University School of Medicine. Board flags: Malpractice Judgment.
Public record actions
| 1997-06-02 | Malpractice judgment | $239,000 · San francisco county superior court · 970124 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$4,830
Medicare paid this office $4,830 for 26 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
26 Original Medicare patients in 2024. Average age 71 · Health risk score 1.99. Sicker patients than 9 in 10 peers; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 73% · Depression 42%.
The office billed $11,001, Medicare allowed $6,170 and paid $4,830; for 34 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 26 | 34 | 71 | 1.99 | $11,001 | $4,830 |
| 2023 | 20 | 21 | 71 | 2.23 | $6,972 | $2,770 |
| 2019 | 12 | 15 | 61 | 3.35 | $8,237 | $825 |
| 2017 | 110 | 600 | 67 | 1.60 | $73,270 | $43,410 |
| 2016 | 151 | 786 | 68 | 1.52 | $132,983 | $65,935 |
| 2015 | 155 | 669 | 68 | 1.60 | $165,325 | $63,857 |
| 2014 | 143 | 522 | 67 | 1.44 | $132,444 | $56,565 |
| 2013 | 144 | 591 | 67 | 1.59 | $150,672 | $69,369 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2019: 1 service
| Return visit (30+ min) | 11 | $726 | $60 |
2017: 7 services
| Long return visit (40+ min) | 86 | $19,988 | $112 |
| Return visit (30+ min) | 39 | $5,845 | $90 |
| Complete ultrasound scan of joint | 25 | $4,537 | $116 |
| Extended patient service without direct patient contact, first hour | 26 | $2,599 | $96 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 44 | $2,296 | $35 |
| Short return visit (20+ min) | 15 | $1,850 | $64 |
| Ultrasound scan of head and neck soft tissue | 13 | $1,510 | $116 |
2016: 7 services
| Long return visit (40+ min) | 121 | $35,223 | $124 |
| Return visit (30+ min) | 49 | $9,606 | $92 |
| New patient visit (60+ min) | 28 | $5,010 | $179 |
| Short return visit (20+ min) | 39 | $3,929 | $63 |
| Complete ultrasound scan of joint | 19 | $2,816 | $117 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 44 | $2,314 | $37 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 14 | $60 | None |
2015: 7 services
| Long return visit (40+ min) | 106 | $29,947 | $123 |
| Return visit (30+ min) | 68 | $11,375 | $95 |
| New patient visit (60+ min) | 41 | $7,359 | $179 |
| Short return visit (20+ min) | 44 | $5,484 | $67 |
| Complete ultrasound scan of joint | 24 | $4,542 | $120 |
| Ultrasound scan of head and neck soft tissue | 11 | $1,564 | $120 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 11 | $94 | None |
2014: 4 services
| Long return visit (40+ min) | 104 | $29,225 | $132 |
| Return visit (30+ min) | 78 | $14,132 | $97 |
| New patient visit (60+ min) | 30 | $5,470 | $182 |
| Short return visit (20+ min) | 40 | $4,269 | $69 |
2013: 5 services
| Long return visit (40+ min) | 127 | $44,683 | $130 |
| Return visit (30+ min) | 52 | $7,958 | $97 |
| New patient visit (60+ min) | 24 | $4,516 | $188 |
| Complete ultrasound scan of joint | 21 | $3,544 | $127 |
| Short return visit (20+ min) | 33 | $3,230 | $67 |
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 22 Part D prescriptions in 2023. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2023 | 22 | None | 0% (0) | None | $690 |
| 2020 | 12 | None | 0% (0) | None | $335 |
| 2019 | 26 | None | 0% (0) | None | $18,188 |
| 2018 | 15 | None | 0% (0) | 0% | $1,131 |
| 2017 | 358 | 64 | 0% (0) | 28% | $390,009 |
| 2016 | 571 | 83 | None | 35% | $667,656 |
| 2015 | 639 | 96 | None | None | $469,285 |
| 2014 | 802 | 106 | None | 33% | $439,867 |
| 2013 | 928 | 99 | None | 30% | $419,128 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2017: 7 drugs
| Humira | 12 | $118,093 | $9,841 |
| Enbrel | 17 | $97,095 | $5,711 |
| Enbrel Sureclick | 17 | $82,908 | $4,877 |
| Hydroxychloroquine Sulfate | 54 | $7,445 | $138 |
| Methotrexate | 36 | $2,868 | $80 |
| Prednisone | 40 | $650 | $16 |
| Montelukast | 18 | $257 | $14 |
2016: 14 drugs
| Enbrel | 52 | $248,332 | $4,776 |
| Humira | 19 | $141,152 | $7,429 |
| Cosentyx | 19 | $121,017 | $6,369 |
| Hydroxychloroquine Sulfate | 80 | $12,870 | $161 |
| Methotrexate | 40 | $3,861 | $97 |
| Prednisone | 75 | $1,505 | $20 |
| Pilocarpine | 11 | $1,063 | $97 |
| Celecoxib | 12 | $1,030 | $86 |
| Synthroid | 12 | $386 | $32 |
| Acyclovir | 13 | $352 | $27 |
| Montelukast | 22 | $305 | $14 |
| Sulindac | 12 | $212 | $18 |
| Meloxicam | 12 | $166 | $14 |
| Naproxen | 12 | $157 | $13 |
2015: 13 drugs
| Enbrel | 48 | $196,554 | $4,095 |
| Humira | 19 | $119,138 | $6,270 |
| Orencia | 13 | $41,262 | $3,174 |
| Hydroxychloroquine Sulfate | 111 | $25,889 | $233 |
| Uloric | 14 | $6,499 | $464 |
| Methotrexate | 38 | $3,942 | $104 |
| Prednisone | 94 | $2,162 | $23 |
| Celecoxib | 13 | $1,926 | $148 |
| Synthroid | 13 | $377 | $29 |
| Montelukast | 27 | $364 | $13 |
| Sulindac | 13 | $180 | $14 |
| Meloxicam | 20 | $139 | $7 |
| Naproxen | 13 | $85 | $7 |
2014: 19 drugs
| Enbrel | 53 | $169,449 | $3,197 |
| Gilenya | 13 | $64,590 | $4,968 |
| Humira | 12 | $55,641 | $4,637 |
| Cellcept | 11 | $16,941 | $1,540 |
| Celebrex | 15 | $9,000 | $600 |
| Doxycycline Hyclate | 27 | $7,356 | $272 |
| Uloric | 15 | $6,869 | $458 |
| Evoxac | 12 | $6,218 | $518 |
| Methotrexate | 53 | $4,786 | $90 |
| Hydroxychloroquine Sulfate | 132 | $3,979 | $30 |
| Mycophenolate Mofetil | 16 | $3,553 | $222 |
| Voltaren | 18 | $2,894 | $161 |
| Benicar | 11 | $1,870 | $170 |
| Prednisone | 87 | $1,585 | $18 |
| Montelukast | 20 | $568 | $28 |
| Methylprednisolone | 20 | $379 | $19 |
| Meloxicam | 34 | $193 | $6 |
| Sulindac | 12 | $113 | $9 |
| Naproxen | 12 | $88 | $7 |
2013: 24 drugs
| Enbrel | 49 | $152,194 | $3,106 |
| Humira | 15 | $58,308 | $3,887 |
| Xeljanz | 14 | $51,545 | $3,682 |
| Kineret | 12 | $29,180 | $2,432 |
| Cellcept | 11 | $24,769 | $2,252 |
| Celebrex | 17 | $7,559 | $445 |
| Doxycycline Hyclate | 40 | $6,983 | $175 |
| Plaquenil | 19 | $5,963 | $314 |
| Evoxac | 13 | $5,859 | $451 |
| Hydroxychloroquine Sulfate | 143 | $3,701 | $26 |
| Cymbalta | 14 | $3,616 | $258 |
| Methotrexate | 43 | $3,217 | $75 |
| Voltaren | 18 | $2,011 | $112 |
| Benicar | 12 | $1,760 | $147 |
| Prednisone | 90 | $1,269 | $14 |
| Mycophenolate Mofetil | 14 | $1,207 | $86 |
| Doxycycline Monohydrate | 12 | $1,060 | $88 |
| Montelukast | 22 | $982 | $45 |
| Acyclovir | 15 | $451 | $30 |
| Methylprednisolone | 13 | $325 | $25 |
| Meloxicam | 26 | $255 | $10 |
| Naproxen | 13 | $179 | $14 |
| Carbamazepine | 13 | $109 | $8 |
| Sertraline | 11 | $59 | $5 |
Money from drug and device companies
$7,095 in 2025
| 2025 | 1 | 2 | $7,095 | $7,095 |
| 2024 | 2 | 13 | $11,990 | $13,500 |
| 2023 | 2 | 3 | $2,150 | $2,906 |
| 2021 | 1 | 1 | $2,596 | $2,596 |
| 2019 | 3 | 3 | $1,663 | $1,810 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Sotyktu | $7,095 | 2 payments
|
See all 2 published payments
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-06-09 | Sotyktu | $3,655 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-05-01 | Sotyktu | $3,440 |
See earlier years (2024, 2023, 2021, 2019)
2024: $13,500
| Boehringer Ingelheim Pharmaceuticals | None | $7,910 | 11 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $5,590 | 2 payments
|
2023: $2,906
| E.R. Squibb & Sons L.L.C. | Sotyktu | $2,150 | 1 payment
|
| Novartis Pharmaceuticals | Cosentyx | $756 | 2 payments
|
2021: $2,596
| Novartis Pharmaceuticals | None | $2,596 | 1 payment
|
2019: $1,810
| E.R. Squibb & Sons L.L.C. | Orencia | $1,663 | 1 payment
|
| GlaxoSmithKline | Benlysta | $92 | 1 payment
|
| F. Hoffmann-La Roche AG | Non-Covered Product | $55 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharma AG · Rheumatology Pipeline Studies · 2023 | This clinician | $13,211 |
| E.R. Squibb & Sons, L.L.C. · Study To Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus Or Primary Sjgren'S Syndrome, Or Branebrutinib Treatment Followed By Open-Label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis · 2021 | This clinician | $3,850 |
| E.R. Squibb & Sons, L.L.C. · Study To Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus Or Primary Sjgren'S Syndrome, Or Branebrutinib Treatment Followed By Open-Label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis · 2020 | This clinician | $2,275 |
| E.R. Squibb & Sons, L.L.C. · Study To Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus Or Primary Sjgren'S Syndrome, Or Branebrutinib Treatment Followed By Open-Label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis · 2022 | This clinician | $2,100 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1669582458
- Licence
- CA G52227California G52227: Current · expires 2028-03-31
- Trained
- Johns Hopkins University School of Medicine, 1982 · 44 years ago
- Group
- Regents of the University of California at Berkeley · University of California San Francisco
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X)
- Mailing address
- 54 Martha Ave, San Francisco, CA, 94131
- NPI first listed
- 2006-08-30
- NPI last updated
- 2011-04-15
This is when the NPI record was last certified, not a medical board exam.